Health Care & Life Sciences » Biotechnology | Audentes Therapeutics Inc.

Audentes Therapeutics Inc.

Audentes Therapeutics Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
37.33 M
Public Float
23.39 M
Audentes Therapeutics Inc.
Stock Exchange NASDAQ Stock Market
EPS
$3.79
Market Cap
$1.6 B
Shares Outstanding
44.29 M
Public Float
37.8 M

Profile

Address
600 California Street
San Francisco California 94108
United States
Employees -
Website http://www.audentestx.com
Updated 07/08/2019
Audentes Therapeutics, Inc. is a biotechnology company, which engages on development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. Its products include AT001 for the treatment of X-Linked Myotubular Myopathy, AT002 for the treatment of Pompe disease, and AT003 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. The company was founded by Matthew R.

Financials

View All

Matthew R. Patterson
Chief Executive Officer & Director
Jennifer Jarrett
Independent Director